DOCSLIB.ORG

Mutations Responsible for Lipodystrophy with Severe Hypertension Activate the Cellular Renin-Angiotensin System

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Mutations Responsible for Lipodystrophy with Severe Hypertension Activate the Cellular Renin-Angiotensin System Liste des publications Auclair M, Vigouroux C, Boccara F, Capel E, Vigeral C, Guerci B, et al. Peroxisome Proliferator-Activated Receptor-? Mutations Responsible for Lipodystrophy With Severe Hypertension Activate the Cellular Renin-Angiotensin System. Arterioscler Thromb Vasc Biol 2013. Svrcek M, Fontugne J, Duval A, Fléjou JF. Inflammatory Bowel Disease-associated Colorectal Cancers and Microsatellite Instability: An Original Relationship. Am J Surg Pathol 2013;37:460-2. Beydon N, Larroquet M, Coulomb A, Jouannic JM, Ducou le Pointe H, Clément A, et al. Comparison between US and MRI in the prenatal assessment of lung malformations. Pediatr Radiol 2013. Brioude F, Bouligand J, Francou B, Fagart J, Roussel R, Viengchareun S, et al. Two Families with Normosmic Congenital Hypogonadotropic Hypogonadism and Biallelic Mutations in KISS1R (KISS1 Receptor): Clinical Evaluation and Molecular Characterization of a Novel Mutation. PLoS One 2013;8:e53896. Watson JA, Bryan K, Williams R, Popov S, Vujanic G, Coulomb A, et al. miRNA profiles as a predictor of chemoresponsiveness in Wilms' tumor blastema. PLoS One 2013;8:e53417. Svrcek M, El-Murr N, Wanherdrick K, Dumont S, Beaugerie L, Cosnes J, et al. Overexpression of microRNAs-155 and 21 targeting mismatch repair proteins in inflammatory bowel diseases. Carcinogenesis 2013. Eckert C, Burghoffer B, Lalande V, Barbut F. Evaluation of the Chromogenic Agar chromID C. difficile. J Clin Microbiol 2013;51:1002-4. Menacer S, Claessens YE, Meune C, Elfassi Y, Wakim C, Gauthier L, et al. Reference range values of troponin measured by sensitive assays in elderly patients without any cardiac signs/symptoms. Clin Chim Acta 2013;417:45-7. Otter JA, Yezli S, Perl TM, Barbut F, French GL. The role of 'no-touch' automated room disinfection systems in infection prevention and control. J Hosp Infect 2013;83:1-13. Sellam J, Kotti S, Fellahi S, Bastard JP, Meyer M, Lioté F, et al. Serum hepcidin level is not an independent surrogate biomarker of disease activity or of radiographic progression in rheumatoid arthritis: results from the ESPOIR cohort. Ann Rheum Dis 2013;72:312-4. Bosselut N, Taibi L, Guéchot J, Zarski JP, Sturm N, Gelineau MC, et al. Including osteoprotegerin and collagen IV in a score-based blood test for liver fibrosis increases diagnostic accuracy. Clin Chim Acta 2013;415:63-8. Drieux L, Decré D, Frangeul L, Arlet G, Jarlier V, Sougakoff W. Complete nucleotide sequence of the large conjugative pTC2 multireplicon plasmid encoding the VIM-1 metallo-?-lactamase. J Antimicrob Chemother 2013;68:97-100. Collura A, Marisa L, Trojan D, Buhard O, Lagrange A, Saget A, et al. Extensive characterization of sphere models established from colorectal cancer cell lines. Cell Mol Life Sci 2013;70:729-42. Sourrouille I, Coulet F, Lefevre JH, Colas C, Eyries M, Svrcek M, et al. Somatic mosaicism and double somatic hits can lead to MSI colorectal tumors. Fam Cancer 2013;12:27-33. Garel C, Rosenblatt J, Moutard ML, Heron D, Gelot A, Gonzales M, et al. Fetal intracerebral hemorrhage and COL4A1 mutation: promise and uncertainty. Ultrasound Obstet Gynecol 2013;41:228-30. Mignot C, Héron D, Bursztyn J, Momtchilova M, Mayer M, Whalen S, et al. Novel mutation in SLC9A6 gene in a patient with Christianson syndrome and retinitis pigmentosum. Brain Dev 2013;35:172-6. Fardet L, Antuna-Puente B, Vatier C, Cervera P, Touati A, Simon T, et al. Adipokine profile in glucocorticoid-treated patients: baseline plasma leptin level predicts occurrence of lipodystrophy. Clin Endocrinol (Oxf) 2013;78:43-51. Fardet L, Vigouroux C, Capeau J. Syndromes lipodystrophiques. Rev Med Interne 2012. Couderc R, Lefevre G, Fiessinger JN. Intérêts des marqueurs biologiques dans les maladies cardiovasculaires. Bull Acad Natl Med 2012;196:217-22. Le Bouc Y, Brioude F. Existe-t-il une relation entre la dose d'hormone de croissance et d'éventuelles complications tumorales ou cardiovasculaires? Bull Acad Natl Med 2012;196:127-35; discussion 135-7. Danchin N, Simon T. Women are the equal of men at last... for sure? EuroIntervention 2012;8:883-5. Tranchart H, Lefèvre JH, Svrcek M, Flejou JF, Tiret E, Parc Y. What is the Incidence of Metastatic Lymph Node Involvement After Significant Pathologic Response of Primary Tumor Following Neoadjuvant Treatment for Locally Advanced Rectal Cancer? Ann Surg Oncol 2012. Gordon CT, Petit F, Oufadem M, Decaestecker C, Jourdain AS, Andrieux J, et al. EFTUD2 haploinsufficiency leads to syndromic oesophageal atresia. J Med Genet 2012;49:737-46. Netchine I, Rossignol S, Azzi S, Brioude F, Le Bouc Y. Imprinted anomalies in fetal and childhood growth disorders: the model of Russell-Silver and Beckwith- Wiedemann syndromes. Endocr Dev 2012;23:60-70. Blondiaux E, Sileo C, Nahama-Allouche C, Moutard ML, Gelot A, Jouannic JM, et al. Periventricular nodular heterotopia: prenatal ultrasound and magnetic resonance findings. Ultrasound Obstet Gynecol 2012. Svrcek M, Fléjou JF. Dysplasie de l'intestin grêle, une dysplasie méconnue. Ann Pathol 2012;32:S58-62. Debiec H, Hanoy M, Francois A, Guerrot D, Ferlicot S, Johanet C, et al. Recurrent membranous nephropathy in an allograft caused by IgG3? targeting the PLA2 receptor. J Am Soc Nephrol 2012;23:1949-54. Kott E, Duquesnoy P, Copin B, Legendre M, Dastot-Le Moal F, Montantin G, et al. Loss-of-function mutations in LRRC6, a gene essential for proper axonemal assembly of inner and outer dynein arms, cause primary ciliary dyskinesia. Am J Hum Genet 2012;91:958-64. Fitzpatrick F, Barbut F. Breaking the cycle of recurrent Clostridium difficile infections. Clin Microbiol Infect 2012;18 Suppl 6:2-4. Barbut F, Lalande V, Eckert C. New molecular methods for the diagnosis of Clostridium difficile infections. Drugs Today (Barc) 2012;48:673-84. Adams O, Cooper G, Fraser C, Hubmann M, Jones G, Plebani M, et al. Collective opinion paper on findings of the 2011 convocation of experts on laboratory quality. Clin Chem Lab Med 2012;50:1547-58. Thiollier C, Lopez CK, Gerby B, Ignacimouttou C, Poglio S, Duffourd Y, et al. Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft models. J Exp Med 2012;209:2017- 31. Aucouturier P. Revoir le dosage des sous-classes d'IgG. Presse Med 2012. Sbidian E, Bousseloua N, Jonard L, Leclerc-Mercier S, Bodemer C, Hadj-Rabia S. Novel Mutation in GJB4 Gene (Connexin 30.3) in a Family with Erythrokeratodermia Variabilis. Acta Derm Venereol 2012. Thauvin-Robinet C, Thomas S, Sinico M, Aral B, Burglen L, Gigot N, et al. OFD1 mutations in males: phenotypic spectrum and ciliary basal body docking impairment. Clin Genet 2012. Vimont S, Boyd A, Bleibtreu A, Bens M, Goujon JM, Garry L, et al. The CTX-M-15- producing Escherichia coli clone O25b: H4-ST131 has high intestine colonization and urinary tract infection abilities. PLoS One 2012;7:e46547. Legendre M, Gonzales M, Goudefroye G, Bilan F, Parisot P, Perez MJ, et al. Antenatal spectrum of CHARGE syndrome in 40 fetuses with CHD7 mutations. J Med Genet 2012;49:698-707. Guyot A, Soupre V, Vazquez MP, Picard A, Rosenblatt J, Garel C, et al. Diagnostic anténatal des fentes labiales avec ou sans fente palatine : étude rétrospective et revue de la littérature. J Gynecol Obstet Biol Reprod (Paris) 2012. Puymirat E, Taldir G, Aissaoui N, Lemesle G, Lorgis L, Cuisset T, et al. Use of invasive strategy in non-ST-segment elevation myocardial infarction is a major determinant of improved long-term survival: FAST-MI (French Registry of Acute Coronary Syndrome). JACC Cardiovasc Interv 2012;5:893-902. Antunes A, Camiade E, Monot M, Courtois E, Barbut F, Sernova NV, et al. Global transcriptional control by glucose and carbon regulator CcpA in Clostridium difficile. Nucleic Acids Res 2012;40:10701-18. Hauck Y, Soler C, Jault P, Mérens A, Gérome P, Nab CM, et al. Diversity of Acinetobacter baumannii in four French military hospitals, as assessed by multiple locus variable number of tandem repeats analysis. PLoS One 2012;7:e44597. Fauroux B, Pepin JL, Boelle PY, Cracowski C, Murris-Espin M, Nove-Josserand R, et al. Sleep quality and nocturnal hypoxaemia and hypercapnia in children and young adults with cystic fibrosis. Arch Dis Child 2012;97:960-6. Barbut F, Rupnik M. Editorial commentary: 027, 078, and others: going beyond the numbers (and away from the hypervirulence). Clin Infect Dis 2012;55:1669- 72. Macé G, Sonigo P, Cormier-Daire V, Aubry MC, Martinovic J, Elie C, et al. Use of 3D helical computed tomography in the prenatal diagnosis of fetal skeletal dysplasia. Ultrasound Obstet Gynecol 2012. Puymirat E, Simon T, Steg PG, Schiele F, Guéret P, Blanchard D, et al. Association of changes in clinical characteristics and management with improvement in survival among patients with ST-elevation myocardial infarction. JAMA 2012;308:998-1006. Stankovic Stojanovic K, Steichen O, Lefevre G, Bachmeyer C, Avellino V, Grateau G, et al. High lactate dehydrogenase levels at admission for painful vaso-occlusive crisis is associated with severe outcome in adult SCD patients. Clin Biochem 2012;45:1578-82. Barbut F, Yezli S, Mimoun M, Pham J, Chaouat M, Otter JA. Reducing the spread of Acinetobacter baumannii and methicillin-resistant Staphylococcus aureus on a burns unit through the intervention of an infection control bundle. Burns 2012. Wen Q, Goldenson B, Silver SJ, Schenone M, Dancik V, Huang Z, et al. Identification of regulators of polyploidization presents therapeutic targets for treatment of AMKL. Cell 2012;150:575-89. Fournier S, Brossier F, Fortineau N, Gillaizeau F, Akpabie A, Aubry A, et al. Long- term control of vancomycin-resistant Enterococcus faecium at the scale of a large multihospital institution: a seven-year experience. Euro Surveill 2012;17. Gras D, Jonard L, Roze E, Chantot-Bastaraud S, Koht J, Motte J, et al.
Load more

Recommended publications
  • Reframing Psychiatry for Precision Medicine
    Reframing Psychiatry for Precision Medicine Elizabeth B Torres 1,2,3* 1 Rutgers University Department of Psychology; [email protected] 2 Rutgers University Center for Cognitive Science (RUCCS) 3 Rutgers University Computer Science, Center for Biomedicine Imaging and Modelling (CBIM) * Correspondence: [email protected]; Tel.: (011) +858-445-8909 (E.B.T) Supplementary Material Sample Psychological criteria that sidelines sensory motor issues in autism: The ADOS-2 manual [1, 2], under the “Guidelines for Selecting a Module” section states (emphasis added): “Note that the ADOS-2 was developed for and standardized using populations of children and adults without significant sensory and motor impairments. Standardized use of any ADOS-2 module presumes that the individual can walk independently and is free of visual or hearing impairments that could potentially interfere with use of the materials or participation in specific tasks.” Sample Psychiatric criteria from the DSM-5 [3] that does not include sensory-motor issues: A. Persistent deficits in social communication and social interaction across multiple contexts, as manifested by the following, currently or by history (examples are illustrative, not exhaustive, see text): 1. Deficits in social-emotional reciprocity, ranging, for example, from abnormal social approach and failure of normal back-and-forth conversation; to reduced sharing of interests, emotions, or affect; to failure to initiate or respond to social interactions. 2. Deficits in nonverbal communicative behaviors used for social interaction, ranging, for example, from poorly integrated verbal and nonverbal communication; to abnormalities in eye contact and body language or deficits in understanding and use of gestures; to a total lack of facial expressions and nonverbal communication.
    [Show full text]
  • A History of Closed Circuit O2 Underwater Breathing Apparatus
    Rubicon Research Repository (http://archive.rubicon-foundation.org) A HISTORY OF CLOSED CIRCUIT OXYGEN UNDEnWATER BRDA'1'HIllG AJ'PARATU'S, by , Dan Quiok Project 1/70 School of Underwater Medicine, H MAS PENGUIN, Naval P.O. Balmoral, IT S W .... 2091. May, 1970 Rubicon Research Repository (http://archive.rubicon-foundation.org) TABLE OF CONTENTS. Foreword. Page No. 1 Introduction. " 2 General History. " 3 History Il: Types of CCOUBA Used In 11 United Kingdom. " History & Types of CCOUBA Used In 46 Italy. " History & Types o:f CCOUBJl. Used In 54 Germany. " History & Types of CCOUEA Used In 67 Frr>.!1ce. " History·& Types of CeOUM Used In 76 United States of America. " Summary. " 83 References. " 89 Acknowledgements. " 91 Contributor. " 91 Alphabetical Index. " 92 Rubicon Research Repository (http://archive.rubicon-foundation.org) - 1 - FOREWORD I am very pleased to have the opportunity of introducing this history, having been responsible for the British development of the CCOt~ for special operations during World War II and afterwards. This is a unique and comprehensive summary of world wide development in this field. It is probably not realised what a vital part closed circuit breathing apparatus played in World War II. Apart from escapes from damaged and sunken submarines by means of the DSEA, and the special attacks on ships by human torpedoes and X-craft, including the mortal damage to the "Tirpitz", an important part of the invasion forces were the landing craft obstruction clearance units. These were special teams of frogmen in oxygen breathing sets who placed demolition charges on the formidable underwater obstructions along the north coast of France.
    [Show full text]
  • Sensory Deficits in a Mouse Model of Christianson Syndrome Tarheen
    Sensory Deficits in a Mouse Model of Christianson Syndrome Tarheen Fatima Department of Physiology McGill University, Montreal April 2019 A thesis submitted to McGill University in partial fulfillment of the requirements of the degree of Master of Science. © Tarheen Fatima 2019 Abstract Christianson Syndrome (CS) is a recently characterized X-linked neurodevelopmental disorder caused by loss-of-function mutations in the gene slc9a6, encoding the endosomal Na+/H+ Exchanger 6 (NHE6). The disorder is associated with developmental delay, intellectual disability, loss of motor coordination, mutism, ataxia, epilepsy, as well as autistic features. In addition to these symptoms, CS patients exhibit elevated pain thresholds to noxious stimuli as well as discomfort at normally innocuous stimuli. The underlying causes of these sensory deficits are yet to be determined. Hence, this study aims at understanding how loss-of-function of NHE6 affects transmission and processing of pain. To this end, we examined the expression of NHE6 in peripheral and central neurons implicated in sensation and interpretation of pain. Additionally, we characterized the nociceptive behaviour of NHE6 knockout (KO) mice using a battery of behaviour tests. Our immunohistochemical experiments demonstrate that NHE6 is highly expressed in nociceptive, small-diameter dorsal root ganglia (DRG) neurons. Moreover, mice lacking NHE6 display decreased responses to noxious mechanical, thermal and chemical stimuli but are more responsive to noxious cold than wild-type littermates. Interestingly, immunohistochemical characterization of DRG tissue from aged NHE6 null mice indicates a decrease in some neuronal subsets suggesting cell death. Finally, using light brush-induced Fos activation in the dorsal horn, we found that the spinal processing of innocuous stimuli is not different between wildtype and NHE6 knockout mice.
    [Show full text]
  • Personal Protective Equipment Solutions for the Oil & Gas Industry Safety Solutions for the Oil & Gas Workforce
    Honeywell Safety Products Personal Protective Equipment Solutions for the Oil & Gas Industry Safety Solutions for the Oil & Gas Workforce Safety first Comprehensive head-to-toe safety solutions Honeywell has united the most respected safety brands in the world to deliver best-in-class safety, quality, and performance to all those who work in hazardous environments. The combined strengths of our leading brands in personal protective equipment (PPE) create a unique set of solutions unmatched in the safety industry. Our ongoing commitment to innovation, combined with our global technology centers, has transformed the industry and created a single, premier source for the most comprehensive solutions available. We are united not only by name, but by our singular focus on being the best safety partner, today and into the future. We are dedicated to more than providing a product or a service: we are committed to protecting human lives. We are Honeywell Safety Products. Solutions for every challenge. From hard hats and eyewear to safety footwear, many workers wear Honeywell Safety Products solutions from head to toe. We incorporate comfort and style in an ergonomic approach to product design that, coupled with our behavior- based education and safety expertise, fosters a workplace culture where workers truly embrace safety. We are where you are. Our network of manufacturing, support and safety specialists includes more than 10,000 people in 30 countries. These committed individuals work in manufacturing plants, research centers, distribution facilities and offices worldwide so local support from our safety specialists is just around the corner at sales and service locations spanning six continents.
    [Show full text]
  • What Is Christianson Syndrome? by Dr
    What is Christianson Syndrome? By Dr. Eric Morrow Christianson syndrome is a genetic disorder that affects brain development. It is an “X-linked” disorder (see “Why is CS found only in boys?” section for a description of what X-linked means). Symptoms of CS usually appear in infancy and include epilepsy and intellectual disability. Although the exact prevalence of Christianson syndrome is unknown, a genetic study by Tarpey and colleagues identified Christianson Syndrome in 2 of about 200 families (about 1% of families with apparent X-linked developmental disabilities). This was among the most common genetic change in X-linked forms of intellectual disability. What are the causes of Christianson syndrome? Christianson syndrome is caused by changes in the gene, SLC9A6. Genes are important because they code for proteins, which carry out essential processes in the cells of our bodies. The SLC9A6 gene codes for the NHE6 protein. NHE6 is part of a family of proteins that are sodium (Na+)/hydrogen (H+) exchangers. The NHE6 protein is found in endosomes, which take up molecules to be destroyed or recycled for other processes in our body. NHE6 makes sure that these endosomes have the correct intra-endosomal acid level by letting in Na into the endosome and getting rid of hydrogen, which is the acid molecule. The acid level regulates protein turnover. My analogy our stomach acid, the acidity in endosomes helps degrade cellular proteins. These genetic changes in SLC9A6 cause the NHE6 protein to not work properly. You may have heard words such as “loss-of-function”, “truncation” or “frame- shift”, which describe how the NHE6 protein cannot be made in the cells to carry out these processes in the endosome.
    [Show full text]
  • Luca Bartolini, MD 1 8/9/2021 CURRICULUM VITAE LUCA
    8/9/2021 CURRICULUM VITAE LUCA BARTOLINI, MD Director, Pediatric Epilepsy Program Hasbro Children’s Hospital Assistant Professor of Pediatrics Assistant Professor of Neurology Assistant Professor of Neurosurgery The Warren Alpert Medical School of Brown University Email: [email protected] EDUCATION: Undergraduate Liceo Classico “Tito Livio”, Padova, Italy Medical School University of Padova School of Medicine, Padova, Italy 09/2000 – 07/2006 Doctor of Medicine (M.D.) POSTGRADUATE TRAINING: Residency Obstetrics and Gynecology University of Parma, Italy 07/2007 – 01/2008 Pediatrics (Pediatric Neurology Track) University of Padova, Italy 04/2008 – 10/2013 Pediatrics Children’s National Medical Center / The George Washington University, Washington DC 07/2012 – 06/2013 Child Neurology Children’s National Medical Center / The George Washington University, Washington DC 07/2013 – 06/2016 Luca Bartolini, MD 1 Fellowship Neuroscience Research Children’s National Medical Center / The George Washington University, Washington DC National Institutes of Health, Bethesda, MD 07/2016 – 06/2017 Epilepsy National Institutes of Health, Bethesda, MD 07/2017 – 06/2018 Clinical Neurophysiology National Institutes of Health, Bethesda, MD 07/2018 – 06/2019 POSTGRADUATE HONORS AND AWARDS: Research Career Symposium Scholarship American Academy of Neurology 02/2015 Pediatric Epilepsy Fellow Pipeline Travel Scholarship Epilepsy Foundation of America 12/2015 Sentinel of Science Award (Top 10% of Researchers contributing to the peer-review of the field of Medicine)
    [Show full text]
  • Amyloid Clearance Defect in Apoe4 Astrocytes Is Reversed by Epigenetic Correction of Endosomal Ph
    Amyloid clearance defect in ApoE4 astrocytes is reversed by epigenetic correction of endosomal pH Hari Prasada and Rajini Raoa,1 aDepartment of Physiology, The Johns Hopkins University School of Medicine, Baltimore, MD 21205 Edited by Reinhard Jahn, Max Planck Institute for Biophysical Chemistry, Goettingen, Germany, and approved June 6, 2018 (received for review January 28, 2018) Endosomes have emerged as a central hub and pathogenic driver ability (7–9). Patients who have CS also show striking age- of Alzheimer’s disease (AD). The earliest brain cytopathology in dependent neurodegeneration, with prominent glial pathology neurodegeneration, occurring decades before amyloid plaques and phosphorylated tau deposits (7). Female carriers have and cognitive decline, is an expansion in the size and number of learning difficulties and behavioral issues, and some present with endosomal compartments. The strongest genetic risk factor for low Mini-Mental State Examination scores suggestive of early sporadic AD is the e4 allele of Apolipoprotein E (ApoE4). Previous cognitive decline (10). Interestingly, NHE6 was among the most studies have shown that ApoE4 potentiates presymptomatic endo- highly down-regulated genes (up to sixfold) in the elderly (70 y) somal dysfunction and defective endocytic clearance of amyloid brain, compared with the adult (40 y) brain (11). These obser- beta (Aβ), although how these two pathways are linked at a cel- vations led us to consider a broader role for NHE6 in neuro- lular and mechanistic level has been unclear. Here, we show that degenerative disorders, including Alzheimer’s disease (AD), a aberrant endosomal acidification in ApoE4 astrocytes traps the major cause of dementia in the elderly.
    [Show full text]
  • Based on a Review of the NOAA Diving Manual, 4
    conditions, polluted water, rebreathers, Nitrox, mixed- gas diving, saturated diving, hyperbaric chambers, hazardous aquatic life, emergency medical care, and accident management. But wait, there's more: the appendices also cover field neurological assessment, various dive tables including saturation and Nitrox, a complete glossary, a very good list of references, and a useful index. If you want to complete your library, then also get: • U.S. Navy Diving Manual, available as a free but large 46MB pdf file on-line (www.supsalv.org/ divingpubs.html#Download) • Scientific Diving Techniques; A Practical Guide for the Research Diver, by John Heine (reviewed in Oceanography, 14(1), by Alice Alldredge) • Scientific Diving: A General Code of Practice, by Nick Flemming and Michael Max • The Encyclopedia of Recreational Diving, 2 °a edi- Comments on Technology Transfer in Diving: tion, Professional Association of diving Instructors, 1996, softcover and CD-ROM [some Based on a Review of the NOAA Diving redundancy with the NOAA Diving Manual, but Manual, 4 'h Edition a good chapter on the Aquatic Realm] Review by Part Two--Tech Transfer Melbourne G. Briscoe What this review is really about is a short essay on Office of Naval Research, Arlington, Virginia USA where the information comes from that goes into books Ronald B. Carmichael like the NOAA Diving Manual, and where it goes. Naval Sea Systems Command, Washington, D.C USA There are five major branches in the world of div- ing: commercial, public safety, military, scientific and Part One- Review recreational. In the United States the Occupational This is nominally a review of a 2001 publication, Safety and Health Administration (OSHA) either regu- the NOAA Diving Manual, Diving for Science and lates these activities or gives waivers if an alternative Technology, 4" edition, NTIS Order Number PB99- regulatory process exists.
    [Show full text]
  • 207/2015 3 Lääkeluettelon Aineet, Liite 1. Ämnena I Läkemedelsförteckningen, Bilaga 1
    207/2015 3 LÄÄKELUETTELON AINEET, LIITE 1. ÄMNENA I LÄKEMEDELSFÖRTECKNINGEN, BILAGA 1. Latinankielinen nimi, Suomenkielinen nimi, Ruotsinkielinen nimi, Englanninkielinen nimi, Latinskt namn Finskt namn Svenskt namn Engelskt namn (N)-Hydroxy- (N)-Hydroksietyyli- (N)-Hydroxietyl- (N)-Hydroxyethyl- aethylprometazinum prometatsiini prometazin promethazine 2,4-Dichlorbenzyl- 2,4-Diklooribentsyyli- 2,4-Diklorbensylalkohol 2,4-Dichlorobenzyl alcoholum alkoholi alcohol 2-Isopropoxyphenyl-N- 2-Isopropoksifenyyli-N- 2-Isopropoxifenyl-N- 2-Isopropoxyphenyl-N- methylcarbamas metyylikarbamaatti metylkarbamat methylcarbamate 4-Dimethyl- ami- 4-Dimetyyliaminofenoli 4-Dimetylaminofenol 4-Dimethylaminophenol nophenolum Abacavirum Abakaviiri Abakavir Abacavir Abarelixum Abareliksi Abarelix Abarelix Abataceptum Abatasepti Abatacept Abatacept Abciximabum Absiksimabi Absiximab Abciximab Abirateronum Abirateroni Abirateron Abiraterone Acamprosatum Akamprosaatti Acamprosat Acamprosate Acarbosum Akarboosi Akarbos Acarbose Acebutololum Asebutololi Acebutolol Acebutolol Aceclofenacum Aseklofenaakki Aceklofenak Aceclofenac Acediasulfonum natricum Asediasulfoni natrium Acediasulfon natrium Acediasulfone sodium Acenocoumarolum Asenokumaroli Acenokumarol Acenocumarol Acepromazinum Asepromatsiini Acepromazin Acepromazine Acetarsolum Asetarsoli Acetarsol Acetarsol Acetazolamidum Asetatsoliamidi Acetazolamid Acetazolamide Acetohexamidum Asetoheksamidi Acetohexamid Acetohexamide Acetophenazinum Asetofenatsiini Acetofenazin Acetophenazine Acetphenolisatinum Asetofenoli-isatiini
    [Show full text]
  • 1 Zkoumadla ANGLICKO–ČESKÁ 2016 Acetic Acid, Dilute R1
    7.4.2016 Zkoumadla ANGLICKO–ČESKÁ 2016 Vysvětlivky Times New Roman bold – název nového nebo změněného zkoumadla v ČL 2009 – Dopl. 2016, názvy označené N, jsou pro zkoumadla použitá v národních článcích Anglický název Český název Acacia Arabská klovatina R Acacia solution Arabská klovatina RS Acebutolol hydrochloride Acebutolol-hydrochlorid R Acetal Acetal R Acetaldehyde Acetaldehyd R Acetaldehyde ammonia trimer trihydrate Acetaldehyd-amoniak trimer trihydrát R Acetic acid, anhydrous Kyselina octová bezvodá R Acetic acid, glacial Kyselina octová ledová R Acetic acid Kyselina octová RS Acetic acid, dilute Kyselina octová zředěná RS Acetic acid, dilute R1 Kyselina octová zředěná RS1 Acetic anhydride Acetanhydrid R Acetic anhydride solution R1 Acetanhydrid RS1 Acetic anhydride-sulfuric acid solution Acetanhydrid v kyselině sírové RS Acetone Aceton R Acetonitrile Acetonitril R Acetonitrile for chromatography Acetonitril pro chromatografii R Acetonitrile R1 Acetonitril R1 Acetoxyvalerenic acid Kyselina acetoxyvalerenová R Acetylacetamide Acetylacetamid R Acetylacetone Acetylaceton R Acetylacetone reagent R1 Acetylaceton RS1 Acetylacetone reagent R2 Acetylaceton RS2 N-Acetyl-ε-caprolactam N-Acetyl-ε-kaprolaktam R Acetyl chloride Acetylchlorid R Acetylcholine chloride Acetylcholin-chlorid R Acetyleugenol Acetyleugenol R N-Acetylglucosamine N-Acetylglukosamin R Acetyl-11-keto-β-boswellic acid Kyselina acetyl-11-keto-β-boswellová R N-Acetylneuraminic acid Kyselina N-acetylneuraminová R N-Acetyltryptophan N-Acetyltryptofan Acetyltyrosine ethyl ester
    [Show full text]
  • Research Resources: Brown University
    7/31/2019 This resource listing is intended as a source of information that can be selectively cut, pasted and edited into Facilities and Other Resources sections of grant submissions. BROWN ENVIRONMENT AND RESOURCES (QUICK SECTION LINKS) ACADEMIC INSTITUTIONS ACADEMIC HEALTH CENTERS ACADEMIC SCHOOLS, COLLEGES, DEPARTMENTS, CENTERS, INSTITUTES AND PROGRAMS CLINICAL RESEARCH SUPPORT COLLABORATING INSTITUTIONS COMMUNITY ENGAGEMENT ORGANIZATIONS COMPUTING AND INFORMATION SERVICES CORE AND SHARED RESEARCH FACILITIES DIVERSITY PROGRAMS EDUCATION AND MENTORING RESOURCES EDUCATION PROGRAMS EDUCATION TECHNOLOGY RESOURCES LIBRARY RESOURCES MULTISPECIALTY PRACTICE GROUPS RESEARCH ADMINISTRATION RESEARCH BUILDINGS RHODE ISLAND & RESEARCH ENVIRONMENT RHODE ISLAND STATEWIDE COLLABORATIVE PROGRAMS BROWN ENVIRONMENT AND RESOURCES – DETAILED TABLE OF CONTENTS WITH LINKS ACADEMIC INSTITUTIONS Brown University – Long Brown University - Short University of Rhode Island (URI) ACADEMIC HEALTH CENTERS Lifespan Health System Care New England (CNE) Health System Providence VA Medical Center (PVAMC) ACADEMIC SCHOOLS, COLLEGES, DEPARTMENTS, CENTERS, INSTITUTES AND PROGRAMS Center - Advance-CTR: Comprehensive Center - Advance-CTR: Comprehensive - Alternative Center - Advance-CTR: Summary Center - Advance Predictive Biology Center - Alcohol and Addiction Studies (CAAS) Center - Biology of Aging Center - Brown Center for Biomedical Informatics (BCBI) Center - Brown Center for the Study of Children at Risk Center - Center for Biomedical Engineering (CBME) Center -
    [Show full text]
  • Organization of Bacou-Dalloz 88 1.4
    Reference document 2004 Reference document 2004 This is a free translation of the Reference document (Document de référence) that was filed with the French Market Authority (Autorité des Marchés Financiers) on April 19, 2005, in accordance with Articles 211 to 211-42 of the AMF’s general regulations. Copies of this reference document are available on request, at no charge, from the Investor Relations department of Bacou-Dalloz at the following address: Paris Nord II, Immeuble Edison, 33 rue des Vanesses, BP 55288 Villepinte, 95958 Roissy CDG Cedex, France; and by telephone at +33 (0)1.49.90.79.74; by fax at +33 (0)1.49.90.79.78; or by email at [email protected]; or on the website of the Autorité des Marchés Financiers (www.amf-france.org). Bacou-Dalloz Reference document 2004 1 2 Reference document 2004 Bacou-Dalloz Contents Chapter Page Chapter Page 1 Financial Report 5 4 Corporate Governance 77 1.1. Management report on the financial year 7 4.1. Board of Directors 79 1.2. Risk management report 11 4.2. Shareholdings by senior executives 84 1.3. Recent developments and future perspectives 15 4.3. Organization of Bacou-Dalloz 88 1.4. Summary financial information 16 4.4. Chairman’s report 91 1.5. Consolidated financial statements 19 4.5. Auditors and audits 99 1.6. Summary of Company financial statements 40 1.7. Liquidity & capital resources 43 5 Shareholder Information 101 5.1. General information about the Company 103 2 Business Overview 45 5.2. Information concerning capital issued 108 2.1.
    [Show full text]